KURA Insider Trading

Insider Ownership Percentage: 5.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,012,768.59

Kura Oncology Insider Trading History Chart

This chart shows the insider buying and selling history at Kura Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Kura Oncology Share Price & Price History

Current Price: $7.39
Price Change: Price Increase of +0.13 (1.79%)
As of 01/21/2025 05:00 PM ET

This chart shows the closing price history over time for KURA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$7.26Closing price on 01/20/25:

SEC Filings (Institutional Ownership Changes) for Kura Oncology (NASDAQ:KURA)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KURA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$385kbought$1.10MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Kura Oncology logo
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Read More on Kura Oncology

Today's Range

Now: $7.39
Low: $7.20
High: $7.44

50 Day Range

MA: $10.30
Low: $7.18
High: $18.57

52 Week Range

Now: $7.39
Low: $6.98
High: $24.17

Volume

2,903,887 shs

Average Volume

1,350,948 shs

Market Capitalization

$574.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Who are the company insiders with the largest holdings of Kura Oncology?

Kura Oncology's top insider shareholders include:
  1. Thomas Malley (Director)
  2. Teresa Brophy Bair (Insider)
  3. Thomas James Doyle (SVP)
  4. Kathleen Ford (COO)
  5. Kirsten Flowers (Insider)
  6. Troy Edward Wilson (CEO)
Learn More about top insider investors at Kura Oncology.

Who are the major institutional investors of Kura Oncology?

Kura Oncology's top institutional shareholders include:
  1. Assenagon Asset Management S.A. — 1.16%
  2. Aaron Wealth Advisors LLC — 0.08%
  3. SG Americas Securities LLC — 0.06%
  4. Harbor Capital Advisors Inc. — 0.06%
Learn More about top institutional investors of Kura Oncology stock.

Which institutional investors are selling Kura Oncology stock?

In the previous quarter, KURA stock was sold by these institutional investors:
  1. Assenagon Asset Management S.A.
  2. Aaron Wealth Advisors LLC
During the previous year, company insiders that have sold Kura Oncology company stock include:
  1. Thomas Malley (Director)
  2. Teresa Brophy Bair (Insider)
  3. Thomas James Doyle (SVP)
  4. Kathleen Ford (COO)
Learn More investors selling Kura Oncology stock.

Which institutional investors are buying Kura Oncology stock?

During the previous quarter, KURA stock was bought by institutional investors including:
  1. SG Americas Securities LLC
  2. Harbor Capital Advisors Inc.